Hello
If you read close;ly… there is a certain regularity which is getting into their business and they are more foussed on monetizing Bio similars … They also have API’s ( linked to their generics ) and some generics and small molecules. Gestation of their business is long. and can be cyclical . They also spend sizable amount on R & D and call it out. They claim to make 30 % margin ex R &D and once R & D pipeline generates sizeable revenue . Numbers will start showing up . They also are probably best CDMO player potentially with 100 % India presence … There are off and on events which impact the companys standing but really not so much to sleep over. There is also an optonality about Bicara which not many people know about.
To round it off about Madams larger than life image, she is what she is and nothing much you can do about it Suffice it to say that there is a capable team below at all levels …
Thanks
Malolan
Subscribe To Our Free Newsletter |